This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.
Frontier Communications' (FTR) Q4 Earnings: What's in Store?
by Zacks Equity Research
Soft demand pattern in voice and video businesses, along with decline in switched access are likely to take a toll on Frontier Communications' (FTR) fourth-quarter revenues.
Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?
by Zacks Equity Research
Solid domestic site leasing business, excellent services and cost control initiatives are likely to drive SBA Communications' (SBAC) fourth-quarter earnings.
What's in Store for Telefonica Brasil (VIV) in Q4 Earnings?
by Zacks Equity Research
Telefonica Brasil's (VIV) fourth-quarter earnings are likely to benefit from its asset base and solid position in key high-value segments.
Why Is Theravance Bio (TBPH) Up 17.9% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Pipeline Strong, Plans Yupelri Launch by Year End
by Zacks Equity Research
Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.
Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.
Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
by Zacks Equity Research
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 6.78% and 21.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Up as CHMP Backs Trelegy Elipta Line Extension
by Zacks Equity Research
Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.
Theravance, Mylan Report Positive Data on COPD Drug Yupelri
by Zacks Equity Research
Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.
Theravance Bio (TBPH) Up 2.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up
by Zacks Equity Research
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q2. Sales beat estimates.
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 38.71% and 135.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Down 1.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Biopharma (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
by Zacks Equity Research
Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.
Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.
Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Biopharma (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
by Zacks Equity Research
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Theravance's NDA for COPD Candidate Gets FDA Acceptance
by Debapriya Chakraborty
The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
by Zacks Equity Research
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.